# US 2021/0180027 A1 · Method for Acclimating and Suspending Vero and Second Order Production Process for Virus

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0180027 A1
- Document ID: US20210180027A1
- Status: Published application
- Kind: A1
- Application number: 16/761,049
- Filed: 2017-11-09
- Published: 2021-06-17
- Earliest claimed: 2017-11-09
- Assignees: Jianshun Biosciences Co., Ltd.
- Applicants: Jianshun Biosciences Co., Ltd.
- Inventors: Shijun Cai; Ruijuan Hou
- Web page: https://patentgrep.com/patent/US20210180027A1

## CPC

- A61K 39/12: Viral antigens
- C12N 5/0686: {Kidney cells}
- A01N 1/162: Temperature processes, e.g. following predefined temperature changes over time
- A61K 39/00: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53)
- A61K 39/215: Coronaviridae, e.g. avian infectious bronchitis virus
- A61P 31/14: for RNA viruses
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- A61K 2039/525: {Virus}
- C12N 2770/18034: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2770/18052: relating to complementing cells and packaging systems for producing virus or viral particles
- C12N 2770/20034: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2770/20051: Methods of production or purification of viral material
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A01N: PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF (preservation of food or foodstuff A23); BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES (preparations for medical, dental or toiletry purposes which kill or prevent the growth or proliferation of unwanted organisms A61K); PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

Disclosed is a second-order culture method for producing a suspended Vero cell vaccine, wherein same comprises the following steps: suspension culture growth of Vero cells, inoculation of a virus, dilution or addition of a production medium, secondary growth of cells, and optionally harvesting and purifying the virus fluid to produce the vaccine.

## Claims

### Claim at position 1

1-14. (canceled)

### Claim 15

A second-order cultivation method for producing vaccines with suspension Vero cells, comprising the following steps:
1) cell growth: suspension Vero cells are grown in a growth medium to 2.0×106 cells/mL˜20.0×106 cells/m L;
2) inoculation: the inoculation amount is between 10−1˜10−5 MOIs, or viruses are inoculated after step 3) according to this inoculation amount;
3) dilution/supplementation of a production medium: Diluting 1 to 5 times with the production medium, and after dilution, the cell density reaches 1.0×106 cells/mL to 10.0×106 cells/mL;
4) secondary growth: secondary growth of cells;
5) optionally, the virus solution is harvested and purified for vaccine preparation.

### Claim 16 (depends on 15)

The second-order cultivation method for producing vaccines with suspension Vero cells according to claim 15, wherein the growth of suspension Vero cells is a suspension cultivation tank cultivation with a cultivation working volume of 30 L and above.

### Claim 17 (depends on 15)

The second-order cultivation method for producing vaccines with suspension Vero cells according to claim 15, wherein the cell density in step 1) is 5.0×106 cells/mL to 16.0×106 cells/mL, preferably, 6.0×106 cells/mL to 15.0×106 cells/mL, most preferably, 10.0×106 cells/mL.

### Claim 18 (depends on 15)

The second-order cultivation method for producing vaccines with suspension Vero cells according to claim 15, wherein the inoculation amount to the cells in step 2) is between 10−1˜10−4 MOIs, more preferably, 10−1˜10−3 MOIs, most preferably, 10−2 MOIs.

### Claim 19 (depends on 15)

The second-order cultivation method for producing vaccines with suspension Vero cells according to claim 15, wherein the production medium for suspension Vero cells in step 3) is diluted 1 to 4 times, more preferably, 1 to 3 times, and most preferably, 2 times.

### Claim 20 (depends on 15)

The second-order cultivation method for producing vaccines with suspension Vero cells according to claim 15, wherein the cell density after inoculation in step 3) is 1.0×106 cells/mL˜10.0×106 cells/mL, preferably, 4.0×106 cells/mL to 10.0×106 cells/mL.

### Claim 21 (depends on 15)

The second-order cultivation method for producing vaccines with suspension Vero cells according to claim 15, wherein the suspension Vero cells are suspension cells used for vaccine production, or suspension Vero cells acclimated from adherent Vero cells and capable of suspension growth and production, preferably, the suspension Vero cells are obtained from adherent Vero cells by low serum acclimation or serum-free acclimation, wherein “serum-free acclimation” means that the acclimated Vero cells can grow and proliferate in a medium without serum, and/or, preferably, suspension Vero cells are obtained from adherent Vero cells by suspension acclimation.

### Claim 22 (depends on 21)

The second-order cultivation method for producing vaccines with suspension Vero cells according to claim 21, wherein the suspension acclimation of adherent Vero cells comprises the following steps:
1) adapting the adherent cells to low serum cultivation;
2) suspension cultivation of the adherent cells adapted to low serum with a total suspension medium.

### Claim 23 (depends on 22)

The second-order cultivation method for producing vaccines with suspension Vero cells according to claim 22, wherein the adherent Vero cell is the adherent Vero cell designated as ATCC accession No. CCL-81.

### Claim 24 (depends on 22)

The second-order cultivation method for producing vaccines with suspension Vero cells according to claim 22, wherein the cultivation adapted low serum of the adherent cells comprises the following low serum adaption steps: a) optionally, thawing the adherent Vero cells, b) resuspending the cells with the low serum medium Celhappy® BD004 (JSB-DP049) plus 5% newborn bovine serum and incubating; c) collecting the cells and reseeding them in a flask such as a T75 flask, adding reduced concentration of serum such as 4%, 3%, or 2% newborn bovine serum, incubating the cells in an incubator at 37° C., 5% CO2; d) passaging the cells and reducing the serum in the low serum medium to 3%, 2%, 1% step by step till the cells can grow normally when the serum concentration is reduced to 1%.

### Claim 25 (depends on 22)

The second-order cultivation method for producing vaccines with suspension Vero cells according to claim 22, wherein suspension cultivation of the adherent cells adapted to low serum with a total suspension medium comprises the following steps: i) resuspending the adherent cells adapted to low serum with the serum-free chemically defined growth medium Celkey® CD Vero 225 (JSB-DP211) in a suspension culture shake flask, pipetting the cell aggregates to make the cells disperse, adjusting the cell seeding density to 0.5 ˜1.0×106 cells/mL; ii) growing the cells to a cell density of 1.0 2.0×106 cells/mL and a viability above 95%, and then passaging the cells; iii) centrifuging the culture of step ii) to collect the cells, repeating steps i)˜ii) until the cell density reaches 2.0×106 cells/mL to 4.0×106 cells/mL after 3 days of cultivation, with a viability above 95%, and a good dispersibility and no large cell aggregates and the highest cell density even reaches 8.0×106 cells/mL to 20.0×106 cells/mL; iv) optionally, centrifuging and collecting the final culture obtained in step iii) and cryopreserving the cells at a concentration of 15.0×106 cells/mL in a process cooling box in a refrigerator at −80° C. for 24 h, and then transferring the cryotube to a liquid nitrogen tank for storage.

### Claim 26 (depends on 15)

The second-order cultivation method for producing vaccines with suspension Vero cells according to claim 15, wherein the virus is a virus that is sensitive to the corresponding suspension Vero cell and is capable of producing the corresponding vaccines, preferably, the virus is selected from the group consisting of rabies vaccine (RV), porcine epidemic diarrhea vaccine (PEDV), Japanese encephalitis virus vaccine, and Polio vaccine.

### Claim 27 (depends on 15)

The second-order cultivation method for producing vaccines with suspension Vero cells according to claim 15, wherein the cell growth temperature is between 35° C. and 37° C., and the virus production temperature after inoculation is between 30° C. and 37° C.

### Claim 28 (depends on 15)

The second-order cultivation method for producing vaccines with suspension Vero cells according to claim 15, wherein the cell growth seeding density is between 0.3×106 cells/mL to 1.0×106 cells/mL, and the growth reaches the highest cell density within 2 to 8 days.
